Vincora Receives FDA Approval to Initiate U.S. Early Feasibility Study of Transcatheter Chordal Repair System

Barchart · 2d ago

MAPLE GROVE, Minn., Oct. 27, 2026 /PRNewswire/ -- Vincora (NeoChord, Inc. d/b/a Vincora), a medical technology company developing transcatheter therapies for mitral valve repair, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) to initiate a U.S. Early Feasibility Study (EFS) of its investigational Transcatheter Chordal Repair System for the treatment of degenerative mitral valve regurgitation.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.